Related Experiment Video
Updated: Dec 6, 2025

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
Published on: January 7, 2019
Anti-JCV antibody index does not change during ocrelizumab-treatment
Torge Rempe1,2, Aaron Carlson1,3, Augusto Miravalle1,3
1Department of Neurology, College of Medicine, University of Florida, Gainesville, USA.
Objective:
To prospectively assess anti-JCV antibody index (AI) and its relationship to immunoglobulin levels in ocrelizumab-treated MS patients.
Methods:
Monocentric prospective observational study over 24 months assessing anti-JCV AI and immunoglobulin levels in MS patients before and after initiation of ocrelizumab.
Results:
No significant change in anti-JCV AI titers was observed 458 ± 300 days after initiation of ocrelizumab (n = 45, 0.7 ± 2.21 vs. 0.6 ± 2.06, p = 0.8). Seroconversion occurred in 1/20 initially anti-JCV seronegative patients. There was no correlation between changes in anti-JCV AI and immunoglobulins.
Conclusion:
Treatment with ocrelizumab is not associated with an increase in anti-JCV AI titers.
More Related Videos
Related Concept Videos
Enzyme-Linked Immunosorbent Assay
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen. Enzyme-substrate reaction allows the antigen to be visualized or...
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Myocarditis II: Clinical Features and Diagnostic Tests
Therapeutic Drug Monitoring: Affecting Factors
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...

